Lexeo CEO acquires 2,623 shares in stock plan

Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c) and 16b-3(d).

Rhea-AI Filing Summary

Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c) and 16b-3(d). Following this award, he directly holds 395,106 shares, including 261,349 restricted stock units.

Insider Trade Summary

Grant/Award: 2,623 shares

Grant/Award 1 txn

Insider Townsend Richard Nolan

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,623	$2.644	$7K

Holdings After Transaction: Common Stock — 395,106 shares (Direct)

Footnotes (2)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
2. F2. Includes 261,349 Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lexeo Therapeutics (LXEO) report for its CEO?

Lexeo Therapeutics reported that CEO Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share. The acquisition occurred under the 2023 Employee Stock Purchase Plan and is exempt under Rule 16b-3(c) and 16b-3(d).

How many Lexeo Therapeutics (LXEO) shares does the CEO hold after this Form 4?

After the reported transaction, CEO Richard Nolan Townsend directly holds 395,106 shares of Lexeo Therapeutics common stock. This total includes 261,349 restricted stock units, which represent share-based awards that typically vest over time according to the company’s equity plans.

What is the nature of the CEO’s Lexeo Therapeutics (LXEO) share acquisition?

The CEO’s acquisition of 2,623 Lexeo Therapeutics shares was classified as a grant or award-type acquisition. It was made pursuant to the 2023 Employee Stock Purchase Plan and reported as exempt from certain short-swing profit rules under SEC Rule 16b-3(c) and 16b-3(d).

Does the Lexeo Therapeutics (LXEO) Form 4 show a purchase or sale on the open market?

The Form 4 does not show an open-market purchase or sale. Instead, it reports an acquisition coded as a grant or award under the 2023 Employee Stock Purchase Plan, which is treated as an exempt transaction under SEC Rule 16b-3 provisions.

What role does the 2023 Employee Stock Purchase Plan play for Lexeo Therapeutics (LXEO)?

The 2023 Employee Stock Purchase Plan allows eligible Lexeo Therapeutics employees, including executives, to acquire company common stock. The CEO’s 2,623-share acquisition was reported as occurring under this plan and qualifies for exemptions under SEC Rule 16b-3(c) and 16b-3(d).

How many restricted stock units does the Lexeo Therapeutics (LXEO) CEO hold?

Within the CEO’s total 395,106 Lexeo Therapeutics shares, 261,349 are restricted stock units. Restricted stock units typically convert into common shares upon vesting, subject to continued service and any performance or time-based conditions set by the company’s plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 09:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A	V	2,623(1)	A	$2.644	395,106(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

2. Includes 261,349 Restricted Stock Units.

	/s/ Youjin Choi, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.